Choose your location:

Choose a Language

Contact us

News

Strategy, appointments, major clinical, medical and regulatory advances, and partnerships: you can find all the latest Ipsen Group press releases here.

September 21, 2018
Ipsen relocating German affiliate to Munich
Events |  News |  Other information News Article
June 3, 2018
Boston and Paris – two rich ecosystems of R&D excellence
News |  Other information News Article
May 30, 2018
Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma
News |  Other information |  Press Releases News Article
May 22, 2018
IPSEN SPONSORS THE STROKE ACTION PLAN FOR EUROPE (2018-2030)
News |  Other information |  Press Releases News Article
March 19, 2018
Ipsen Named One of the Best Workplaces in Ireland
News |  Uncategorized News Article
March 19, 2018
LivingWithNETs.com awarded as Most valuable patient initiative by Eyeforpharma Awards 2018*
News |  Uncategorized News Article
March 15, 2018
Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
News |  Uncategorized News Article
February 15, 2018
International Childhood Cancer Day, Ipsen mobilizes its teams
News |  Uncategorized News Article
February 14, 2018
Ipsen’s Full Year 2017 Financial Results
News |  Uncategorized News Article
January 15, 2018
Ipsen and Exelixis to host joint investor briefing on Phase 3 CELESTIAL trial results presented at ASCO GI
News |  Uncategorized News Article
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023